A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS): Assessment of Localized Therapeutic Activity by Blinded Observation and Lateral Transplantation (ALTA-BOLT)
Latest Information Update: 13 Jul 2026
At a glance
- Drugs Human glial restricted progenitor cells based therapeutics (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; First in man
- Acronyms ALTA-BOLT
- Sponsors Q Therapeutics
Most Recent Events
- 08 Jul 2026 Planned End Date changed from 1 Dec 2025 to 1 Dec 2028.
- 08 Jul 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2028.
- 08 Jul 2026 Planned initiation date changed from 1 Mar 2024 to 1 Dec 2026.